Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation

Hospital Universitario Dr. Jose E. Gonzalez6 enrolled

Overview

Generic plerixafor use at reduced-dose for mobilization on HSCT transplant

The objective of this study is to demonstrate that the use of a low dose of the generic form of a drug called plerixafor is effective in increasing the amount of hematopoietic cells (stem cells) in your blood, which will then be collected for your transplant. Plerixafor is a very effective medicine that is already used for this purpose, however its high cost limits its use in all patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

SINGLE

Enrollment

Conditions

Lymphoma Myeloma

Interventions

CelrixaforDRUG

Use a reduced-dose of generic plerixafor

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with lymphoma or multiple myeloma who are candidates for autoHSCT * Patients \> 18 years old who signed our informed consent * Normal CBC count (Hb \> 10, WBC 4.0-11.00, plt \> 100,000) Exclusion Criteria: * Patients with HIV, Hepatitis C, Hepatitis B diagnosis * Pregnant women

Locations (1)

Universidad Autónoma de Nuevo León

Monterrey, Nuevo León, Mexico

Outcomes

Primary Outcomes

Post-RD plerixafor increase in CD34+/μL pre-count, final CD34+ cell yield and harvest

The objective of this study is to demonstrate that the use of a low dose of the generic form of plerixafor is effective in increasing the amount of hematopoietic cells (stem cells).

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.